Results: Overall, less than 50% of patients achieved their LDL-C treatment goal, with patients at higher risk of a cardiovascular event being less likely to attain their target. Nearly, three-quarters of patients in this study were considered high or very high risk, with only 10% of high-risk patients reaching their treatment goal. Organization projects that CVD will remain the leading cause of death worldwide in future years, with deaths from CVD estimated to increase to 23.3 million by 2030 [1, 2] .
Currently, over 80% of CVD deaths occur in low-and middle-income countries [1] . This has been attributed to the fact that people in these countries are typically exposed to more risk factors, such as tobacco and dyslipidemia [high apolipoprotein B (ApoB):apolipoprotein A1 (ApoA1) ratio] [3] . In addition, they are likely to have less access to early detection and prevention programs than patients in more developed countries [3] . These factors also contribute to the fact that the mean age [±standard deviation (SD)] of first presentation of acute myocardial infarction (AMI) has been observed to be 51. 2 
(±10.3) years in Middle
Eastern countries, approximately 10 years younger than in other regions of the world [3, 4] . Furthermore, the Middle East has the highest proportion of first AMI in individuals aged 40 years or younger [4] .
In Egypt, the age-standardized annual death rate from CVD is over 400 per 100,000 population, and this compares to rates of less than 150 per 100,000 population in some European countries [5] . The Egyptian National Hypertension Project, which surveyed over 6,700 subjects, reported the national incidence of coronary heart disease to be 8.3% [5] . The incidence was higher in women than men (8.9% versus 8.0%, respectively) and higher in urban populations than rural populations (8.8%
versus 7.2%, respectively).
There is epidemiological evidence that elevated total serum cholesterol, specifically elevated levels of low-density lipoprotein cholesterol (LDL-C), is strongly correlated with the risk of coronary heart disease [6] [7] [8] [9] [10] . Thus, a principal intervention to reduce the risk of cardiovascular events in patients with CVD is to control the level of circulating lipids, particularly LDL-C [8, 11, 12] . Clinical intervention studies have shown that the impact of lipid-lowering treatment is primarily dependent on the individual's baseline risk of a cardiovascular event, and that the reduction in risk of an event subsequently occurring is proportional to the degree of LDL-C lowering achieved by treatment [8, [11] [12] [13] . Therefore, 
METHODS

Study Design
This was a multicenter, observational study of patients receiving lipid-lowering 
Study Objectives
The primary objective of the study was to 
Study Inclusion Criteria
Subjects fulfilling the following inclusion criteria were enrolled in the study:
age C18 years; receiving lipid-lowering drug treatment for at least 3 months with no dose change for at least 6 weeks; and provision of written informed consent to participate in the study and comply with study procedures.
Study Procedures
The study planned to enroll 1,100 randomly selected patients being treated by 78 specialists and primary care physicians located in Cairo and Alexandria, Egypt. The required sample size was calculated to ensure that the primary and secondary endpoints could be estimated with sufficient precision to represent the heterogeneity of this population, and was based on an estimated 50% of participants being expected to achieve their treatment goal.
Prior to assessing their first study participant, programmatically by an expert panel.
Statistical Analysis
The statistical analysis was of a descriptive nature. Continuous data are described by mean, SD, median, minimum and maximum values. Categorical data are described by the number and percentage of subjects in each category. Missing data were not included in the calculation of proportions. The association between achievement of LDL-C goals and patient/physician variables was analyzed by a multivariate logistic regression model. The mean laboratory blood values for all variables analyzed in the study are given in Table 2 .
Overall, 32.5% of patients achieved their LDL-C treatment goal according to criteria Table 5 . HbA1c glycosylated hemoglobin, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, SD standard deviation
Results of the Patient Questionnaire
All of the 1,043 patients available for analysis returned the questionnaire with at least one question completed. Most patients had heard about, or been told about, LDL-C and HDL-C (78.0% and 70.7%, respectively). The majority (80.6%) had been informed of their cholesterol levels by their physician, and 76.0% had been given a target cholesterol level. Additional responses to the patients' questionnaire are shown in Table 6 .
Multivariate Analysis of Factors Associated with Achieving LDL-C Treatment Goal
The main patient and physician factors that were significantly associated with patients In contrast, over 65% of patients in the low or medium-low risk categories successfully attained their treatment goal, although it should be noted that these combined patient These findings conflict with the result that most investigators (74%) stated that they used guidelines to establish individual target cholesterol levels for patients, most commonly the NCEP ATP III 2004 updated guidelines. The findings are also in contrast to the beliefs of the treating physicians, as more than 60% of investigators either agreed or strongly agreed with the statement that they felt a sufficient number of patients reached their target levels.
However, the finding is more in line with patient perception, as only around 50% of patients stated that they were satisfied with their treatment.
Evaluation of sub-groups of patients with established risk factors for CVD showed that hypercholesterolemia was particularly poorly managed in patients who were current smokers (18.9% of participants) or were diabetic (48.5% of participants), whereas only 17.3% and 20.6% of patients, respectively, The majority of patients in this study (85.9%) were prescribed statins, which are well established as an effective treatment of dyslipidemia [15, 16] . The most commonly prescribed statins were atorvastatin and to adapt an individual's response to treatment may be a factor in the overall failure of patients Patient compliance to treatment is another factor that could influence treatment outcomes.
In this study, 12% of patients admitted forgetting to take their prescribed medication more than once a week, and 16% stated that they forgot no more than once a month. Furthermore, in the multivariate analysis, forgetting to take tablets was strongly correlated with not attaining treatment goals.
A report of the CEPHEUS study in six Middle Eastern countries (Bahrain, Oman, Qatar, UAE, KSA and Kuwait), concluded that hypercholesterolemia was sub-optimally managed across these countries, particularly in those with a high or very high risk of a cardiovascular event [17] . In the overall regional analysis, 52% of patients attained Cardiology and American Heart Association has concluded that there was insufficient evidence to support the continued use of LDL-C or non-HDL-C treatment targets, instead recommending different intensities of statin treatment for patients based on four statin benefit groups [24] . While it would be interesting to apply the updated guidance to the results of this study, due to the enrolment criterion of patients already receiving lipidlowering drugs for at least 3 months there are no baseline measurements against which to compare. Additionally, resource limitations prevent us from re-classifying patients into the revised risk groups to perform re-analyses against the latest guidance, or from providing additional statistical analyses on comparisons between risk groups.
CONCLUSION
In conclusion, this study found that hypercholesterolemia is not being effectively managed in many at-risk patients in Egypt. The majority of patients enrolled in the study, all of whom were being actively treated with lipidlowering medication, were considered at high risk of a cardiovascular event, and hypercholesterolemia was particularly poorly managed in this group. Initiatives to improve physicians' management of these patients and patient compliance to treatment are urgently needed. 
